1. Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy

   • Richard C. Becker
   • A. Phillip Owens III
   • Sakthivel Sadayappan

   ReviewPaper 02 January 2020 Pages: 177 - 183

   

2. The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials

   • Mohammed Osman
   • Peter D. Farjo
   • Sudarshan Balla

   ReviewPaper 21 November 2019 Pages: 184 - 191

   

3. Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study

   • Ying X. Gue
   • Rahim Kanji
   • Diana A. Gorog

   OriginalPaper Open access 23 December 2019 Pages: 192 - 198

   

4. Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin

   • Damon E. Houghton
   • Alexander Lekah
   • Waldemar E. Wysokinski

   OriginalPaper 17 August 2019 Pages: 199 - 205

   

5. Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels

   • Alex M. Ebied
   • Tammy Li
   • Yiqing Chen

   OriginalPaper 05 September 2019 Pages: 206 - 213

6. Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial

   • Walter Ageno
   • Renato D. Lopes
   • Alexander T. Cohen

   OriginalPaper 06 September 2019 Pages: 214 - 219

7. Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism

   • Ming Sheng Lim
   • Dee Nandurkar
   • Sanjeev Chunilal

   OriginalPaper 06 September 2019 Pages: 220 - 227

   

8. Induction of tissue factor expression by anti-β2-glycoprotein I is mediated by tumor necrosis factor α

   • Anne Hollerbach
   • Nadine Müller-Calleja
   • Karl J. Lackner

   OriginalPaper 15 October 2019 Pages: 228 - 234

   

9. Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction

   • Ugochukwu Shola Owolabi
   • Alok Ravindra Amraotkar
   • Andrew Paul DeFilippis

   OriginalPaper 05 December 2019 Pages: 235 - 244

   

10. Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status

    • Bohyun Kim
    • Seongsoo Jang
    • Chan-Jeoung Park

    OriginalPaper 10 September 2019 Pages: 245 - 250

    

11. Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study

    • Maria Cristina Vedovati
    • Maria Giulia Mosconi
    • Cecilia Becattini

    OriginalPaper 13 September 2019 Pages: 251 - 258

    

12. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients

    • Jacob T. Beyer
    • Stuart E. Lind
    • Tyree H. Kiser

    OriginalPaper 26 September 2019 Pages: 259 - 267

    

13. High incidence of under-treated atrial fibrillation: perspectives from an Asian Stroke Endovascular Thrombectomy Registry

    • Benjamin Yong-Qiang Tan
    • Aloysius Sheng-Ting Leow
    • Leonard Leong-Litt Yeo

    Letter to the Editor 13 December 2019 Pages: 268 - 270

    

14. Direct oral anticoagulants: a review on the current role and scope of reversal agents

    • Rahul Chaudhary
    • Tushar Sharma
    • Paul Gurbel

    ReviewPaper 11 September 2019 Pages: 271 - 286

    

15. Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center

    • Sweta Meet Patel
    • Tina Wang
    • Mikhail Akbashev

    OriginalPaper 09 October 2019 Pages: 287 - 293

    

16. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care

    • Markus Gulilat
    • Denise Keller
    • Ute I. Schwarz

    OriginalPaper 28 September 2019 Pages: 294 - 303

    

17. Factors associated with women’s adherence to postpartum thromboprophylaxis

    • Amihai Rottenstreich
    • Adi Karlin
    • Misgav Rottenstreich

    OriginalPaper 06 September 2019 Pages: 304 - 311

18. Congenital fibrinogen disorders with repeated thrombosis

    • Xiuli Zhang
    • Chuang Zhang
    • Xueli Guo

    OriginalPaper 21 September 2019 Pages: 312 - 315

    

19. Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project

    • Maria R. Bernstein
    • Libiny John
    • Alex C. Spyropoulos

    BriefCommunication 02 January 2020 Pages: 316 - 320

    

20. Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more

    • Bernhard Wernly
    • Deepak L. Bhatt
    • Christian Jung

    BriefCommunication 03 December 2019 Pages: 321 - 324

    

21. The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes

    • Leonard Naymagon
    • Douglas Tremblay
    • John Mascarenhas

    OriginalPaper 06 September 2019 Pages: 325 - 331

22. Initiation of a fixed- dose four- factor prothrombin complex concentrate protocol

    • Ajay Kumar Mishra
    • Kamal Kant Sahu
    • Susan V. George

    Letter to the Editor 16 December 2019 Pages: 332 - 333

23. A case report of severe bleeding due to lupus anticoagulant hypoprothrombinemia syndrome

    • Elsa Meireles
    • Filipe Machado
    • Ana Spínola

    Report 12 September 2019 Pages: 334 - 336